Search

Your search keyword '"El-Rayes, Bassel F."' showing total 884 results
Start Over Author "El-Rayes, Bassel F."
884 results on '"El-Rayes, Bassel F."'

6. A potent and selective pan-RAS inhibitor, ADT-1004, targeting complex KRAS mutations for pancreatic cancer.

Author

Piazza, Gary A., primary, Bandi, Reddy D. S., additional, Ganji, Pumachandra N., additional, Foote, Jeremy B., additional, Keeton, Adam B., additional, Mattox, Tyler Ernest, additional, Chen, Xi, additional, Hardy, Cherlene, additional, Berry, Kristy, additional, Maxuitenko, Yulia, additional, Manne, Upender, additional, Boyd, Michael R., additional, Buchsbaum, Donald J., additional, and El-Rayes, Bassel F., additional

Published
2024
Full Text
View/download PDF

7. Navigating the clinical trial maze: Identifying barriers to enrollment among patients with advanced cancer in a community-academic partnership.

Author

Desai, Aakash, primary, Kumar, Madhan Srinivasan, additional, Huggins, Tiffany, additional, McNeeley, Ellen, additional, Jahan, Nusrat, additional, Yunus, Furhan, additional, Khalil, Maya, additional, Kemnade, Jan Ole, additional, El-Rayes, Bassel F., additional, Akce, Mehmet, additional, and Arend, Rebecca Christian, additional

Published
2024
Full Text
View/download PDF

8. Evaluation of a novel Pan-RAS/β-Catenin inhibitor, ADT-030, for treatment of pancreatic cancer.

Author

Piazza, Gary A, primary, Bandi, Reddy DS, additional, Ganji, Pumachandra N, additional, Foote, Jeremy B, additional, Keeton, Adam B, additional, Mattox, Tyler Ernest, additional, Chen, Xi, additional, Hardy, Cherlene, additional, Berry, Kristy, additional, Maxuitenko, Yulia, additional, Manne, Upender, additional, Buchsbaum, Donald J, additional, El-Rayes, Bassel F., additional, and Boyd, Michael R, additional

Published
2024
Full Text
View/download PDF

12. National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer

Author

George, Thomas J, Franke, Aaron J, Chakravarthy, A Bapsi, Das, Prajnan, Dasari, Arvind, El‐Rayes, Bassel F, Hong, Theodore S, Kinsella, Timothy J, Landry, Jerome C, Lee, James J, Monjazeb, Arta M, Jacobs, Samuel A, Raben, David, Rahma, Osama E, Williams, Terence M, Wu, Christina, Coleman, C Norman, Vikram, Bhadrasain, and Ahmed, Mansoor M

Subjects
Digestive Diseases, Cancer, Clinical Research, Patient Safety, Biotechnology, Colo-Rectal Cancer, Good Health and Well Being, Antineoplastic Agents, Immunological, B7-H1 Antigen, Biological Products, Colorectal Neoplasms, HSP90 Heat-Shock Proteins, Herpesvirus 1, Human, Humans, Immunotherapy, Mitogen-Activated Protein Kinases, Molecular Targeted Therapy, National Cancer Institute (U.S.), Protein Kinase C, Pyrimidine Nucleosides, Radiation-Sensitizing Agents, United States, abscopal effect, chemoradiotherapy, colorectal cancer, immunotherapy, precision radiation medicine, radiation biology, radiation therapy, radiosensitization, rectal cancer, targeted therapeutics, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

Colorectal cancer (CRC) represents a major public health problem as the second leading cause of cancer-related mortality in the United States. Of an estimated 140,000 newly diagnosed CRC cases in 2018, roughly one-third of these patients will have a primary tumor located in the distal large bowel or rectum. The current standard-of-care approach includes curative-intent surgery, often after preoperative (neoadjuvant) radiotherapy (RT), to increase rates of tumor down-staging, clinical and pathologic response, as well as improving surgical resection quality. However, despite advancements in surgical techniques, as well as sharpened precision of dosimetry offered by contemporary RT delivery platforms, the oncology community continues to face challenges related to disease relapse. Ongoing investigations are aimed at testing novel radiosensitizing agents and treatments that might exploit the systemic antitumor effects of RT using immunotherapies. If successful, these treatments may usher in a new curative paradigm for rectal cancers, such that surgical interventions may be avoided. Importantly, this disease offers an opportunity to correlate matched paired biopsies, radiographic response, and molecular mechanisms of treatment sensitivity and resistance with clinical outcomes. Herein, the authors highlight the available evidence from preclinical models and early-phase studies, with an emphasis on promising developmental therapeutics undergoing prospective validation in larger scale clinical trials. This review by the National Cancer Institute's Radiation Research Program Colorectal Cancer Working Group provides an updated, comprehensive examination of the continuously evolving state of the science regarding radiosensitizer drug development in the curative treatment of CRC.

Published
2019

13. Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma

Author

Ravindranathan, Sruthi, Passang, Tenzin, Li, Jian-Ming, Wang, Shuhua, Dhamsania, Rohan, Ware, Michael Brandon, Zaidi, Mohammad Y., Zhu, Jingru, Cardenas, Maria, Liu, Yuan, Gumber, Sanjeev, Robinson, Brian, Sen-Majumdar, Anish, Zhang, Hanwen, Chandrakasan, Shanmuganathan, Kissick, Haydn, Frey, Alan B., Thomas, Susan N., El-Rayes, Bassel F., Lesinski, Gregory B., and Waller, Edmund K.

Published
2022
Full Text
View/download PDF

17. Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group Trial (E3205)

Author

Garg, Madhur K, Zhao, Fengmin, Sparano, Joseph A, Palefsky, Joel, Whittington, Richard, Mitchell, Edith P, Mulcahy, Mary F, Armstrong, Karin I, Nabbout, Nassim H, Kalnicki, Shalom, El-Rayes, Bassel F, Onitilo, Adedayo A, Moriarty, Daniel J, Fitzgerald, Thomas J, and Benson, Al B

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Clinical Trials and Supportive Activities, Clinical Research, Cancer, Digestive Diseases, Evaluation of treatments and therapeutic interventions, 6.5 Radiotherapy and other non-invasive therapies, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Anus Neoplasms, Carcinoma, Squamous Cell, Cetuximab, Chemoradiotherapy, Cisplatin, Disease-Free Survival, Female, Fluorouracil, Humans, Immunocompetence, Male, Middle Aged, Neoplasm Staging, Survival Rate, Clinical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Purpose Squamous cell carcinoma of the anal canal (SCCAC) is characterized by high locoregional failure (LRF) rates after sphincter-preserving definitive chemoradiation (CRT) and is typically associated with anogenital human papilloma virus infection. Because cetuximab enhances the effect of radiation therapy in human papilloma virus-associated oropharyngeal squamous cell carcinoma, we hypothesized that adding cetuximab to CRT would reduce LRF in SCCAC. Methods Sixty-one patients with stage I to III SCCAC received CRT including cisplatin, fluorouracil, and radiation therapy to the primary tumor and regional lymph nodes (45 to 54 Gy) plus eight once-weekly doses of concurrent cetuximab. The study was designed to detect at least a 50% reduction in 3-year LRF rate (one-sided α, 0.10; power 90%), assuming a 35% LRF rate from historical data. Results Poor risk features included stage III disease in 64% and male sex in 20%. The 3-year LRF rate was 23% (95% CI, 13% to 36%; one-sided P = .03) by binomial proportional estimate using the prespecified end point and 21% (95% CI, 7% to 26%) by Kaplan-Meier estimate in a post hoc analysis using methods consistent with historical data. Three-year rates were 68% (95% CI, 55% to 79%) for progression-free survival and 83% (95% CI, 71% to 91%) for overall survival. Grade 4 toxicity occurred in 32%, and 5% had treatment-associated deaths. Conclusion Although the addition of cetuximab to chemoradiation for SCCAC was associated with lower LRF rates than historical data with CRT alone, toxicity was substantial, and LRF still occurs in approximately 20%, indicating the continued need for more effective and less toxic therapies.

Published
2017

28. Substaging Nodal Status in Ampullary Carcinomas has Significant Prognostic Value: Proposed Revised Staging Based on an Analysis of 313 Well-Characterized Cases

Author

Balci, Serdar, Basturk, Olca, Saka, Burcu, Bagci, Pelin, Postlewait, Lauren M, Tajiri, Takuma, Jang, Kee-Taek, Ohike, Nobuyuki, Kim, Grace E, Krasinskas, Alyssa, Choi, Hyejeong, Sarmiento, Juan M, Kooby, David A, El-Rayes, Bassel F, Knight, Jessica H, Goodman, Michael, Akkas, Gizem, Reid, Michelle D, Maithel, Shishir K, and Adsay, Volkan

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Ampulla of Vater, Common Bile Duct Neoplasms, Female, Follow-Up Studies, Humans, Lymph Nodes, Male, Middle Aged, Neoplasm Staging, Pancreatic Neoplasms, Prognosis, Survival Rate, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundCurrent nodal staging (N-staging) of ampullary carcinoma in the TNM staging system distinguishes between node-negative (N0) and node-positive (N1) disease but does not consider the metastatic lymph node (LN) number.MethodsOverall, 313 patients who underwent pancreatoduodenectomy for ampullary adenocarcinoma were categorized as N0, N1 (1-2 metastatic LNs), or N2 (≥3 metastatic LNs), as proposed by Kang et al. Clinicopathological features and overall survival (OS) of the three groups were compared.ResultsThe median number of LNs examined was 11, and LN metastasis was present in 142 cases (45 %). When LN-positive cases were re-classified according to the proposed staging system, 82 were N1 (26 %) and 60 were N2 (19 %). There was a significant correlation between proposed N-stage and lymphovascular invasion, perineural invasion, increased tumor size (each p < 0.001), and surgical margin positivity (p = 0.001). The median OS in LN-negative cases was significantly longer than that in LN-positive cases (107.5 vs. 32 months; p < 0.001). Patients with N1 and N2 disease had median survivals of 40 and 24.5 months, respectively (p < 0.0001). In addition, 1-, 3-, and 5-year survivals were 88, 76, 62 %, respectively, for N0; 90, 55, 31.5 %, respectively, for N1; and 68, 34, 30 %, respectively for N2 (p < 0.001). Even with multivariate modeling, the association between higher proposed N stage and shorter survival persisted (hazard ratio 1.6 for N1 and 1.9 for N2; p = 0.018).ConclusionsClassification of nodal status in ampullary carcinomas based on the number of metastatic LNs has a significant prognostic value. A revised N-staging classification system should be incorporated into the TNM staging of ampullary cancers.

Published
2015

31. Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma

Author

Harvey, R. Donald, Carthon, Bradley C., Lewis, Colleen, Hossain, Mohammad S., Zhang, Chao, Chen, Zhengjia, Harris, Wayne B., Alese, Olatunji B., Shaib, Walid, Bilen, Mehmet A., Lawson, David H., Wu, Christina, Steuer, Conor E., El-Rayes, Bassel F., Khuri, Fadlo R., Lonial, Sagar, Waller, Edmund K., Ramalingam, Suresh S., and Owonikoko, Taofeek K.

Published
2020
Full Text
View/download PDF

33. Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials

Author

Martini, Dylan J., Liu, Yuan, Shabto, Julie M., Lewis, Colleen, Kline, Meredith R., Collins, Hannah, Akce, Mehmet, Kissick, Haydn T., Carthon, Bradley C., Shaib, Walid L., Alese, Olatunji B., Pillai, Rathi N., Steuer, Conor E., Wu, Christina S., Lawson, David H., Kudchadkar, Ragini R., Master, Viraj A., El-Rayes, Bassel F., Ramalingam, Suresh S., Owonikoko, Taofeek K., Harvey, R. Donald, and Bilen, Mehmet Asim

Published
2019
Full Text
View/download PDF

36. Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer

Author

Akce, Mehmet, primary, Farran, Batoul, additional, Switchenko, Jeffrey M, additional, Rupji, Manali, additional, Kang, Sandra, additional, Khalil, Lana, additional, Ruggieri-Joyce, Amanda, additional, Olson, Brian, additional, Shaib, Walid L, additional, Wu, Christina, additional, Alese, Olatunji B, additional, Diab, Maria, additional, Lesinski, Gregory B, additional, and El-Rayes, Bassel F, additional

Published
2023
Full Text
View/download PDF

37. Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers

Author

Khan, Husain Yar, primary, Nagasaka, Misako, additional, Aboukameel, Amro, additional, Alkhalili, Osama, additional, Uddin, Md. Hafiz, additional, Bannoura, Sahar F., additional, Mzannar, Yousef, additional, Azar, Ibrahim, additional, Beal, Eliza W., additional, Tobon, Miguel E., additional, Kim, Steve H., additional, Beydoun, Rafic, additional, Baloglu, Erkan, additional, Senapedis, William, additional, El-Rayes, Bassel F., additional, Philip, Philip A., additional, Mohammad, Ramzi M., additional, Shields, Anthony F., additional, Al Hallak, Mohammed Najeeb, additional, and Azmi, Asfar S., additional

Published
2023
Full Text
View/download PDF

39. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

Author

Mazzaferro, Vincenzo, El-Rayes, Bassel F., Droz dit Busset, Michele, Cotsoglou, Christian, Harris, William P., Damjanov, Nevena, Masi, Gianluca, Rimassa, Lorenza, Personeni, Nicola, Braiteh, Fadi, Zagonel, Vittorina, Papadopoulos, Kyriakos P., Hall, Terence, Wang, Yunxia, Schwartz, Brian, Kazakin, Julia, Bhoori, Sherrie, de Braud, Filippo, and Shaib, Walid L.

Published
2019
Full Text
View/download PDF

41. Novel Pan-RAS Inhibitor ADT-007 Induces Tumor Regression in Mouse Models of GI Cancer

Author

Foote, Jeremy, primary, Mattox, Tyler E, additional, Keeton, Adam B, additional, Smith, Forrest T, additional, Berry, Kristy L, additional, Ward, Antonio B, additional, Yoon, Karina J, additional, Sarvesh, Sujith, additional, Nagaraju, Ganji P, additional, Maxuitenko, Yulia, additional, Chen, Xi, additional, Valiyaveettil,, Jacob, additional, Carstens, Julienne L, additional, Yang, Jennifer, additional, Yang, Jenny, additional, Buchsbaum, Donald J, additional, Zhou, Gang, additional, Nurmmedov, Elmar, additional, Babic, Ivan, additional, Gaponenko, Vadim, additional, Abdelkarim, Hazem, additional, Boyd, Michael R, additional, El-Rayes, Bassel F, additional, and Piazza, Gary A, additional

Published
2023
Full Text
View/download PDF

43. Non-ampullary–duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas

Author

Xue, Yue, Vanoli, Alessandro, Balci, Serdar, Reid, Michelle M, Saka, Burcu, Bagci, Pelin, Memis, Bahar, Choi, Hyejeong, Ohike, Nobuyike, Tajiri, Takuma, Muraki, Takashi, Quigley, Brian, El-Rayes, Bassel F, Shaib, Walid, Kooby, David, Sarmiento, Juan, Maithel, Shishir K, Knight, Jessica H, Goodman, Michael, Krasinskas, Alyssa M, and Adsay, Volkan

Published
2017
Full Text
View/download PDF

44. Advances in Immunotherapy for Hepatocellular Carcinoma (HCC).

Author

Bicer, Fuat, Kure, Catrina, Ozluk, Anil A., El-Rayes, Bassel F., and Akce, Mehmet

Subjects
HEPATOCELLULAR carcinoma, CIRCULATING tumor DNA, IMMUNE checkpoint inhibitors, TUMOR markers, IMMUNOTHERAPY
Abstract

Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related deaths in the world. More than half of patients with HCC present with advanced stage, and highly active systemic therapies are crucial for improving outcomes. Immune checkpoint inhibitor (ICI)-based therapies have emerged as novel therapy options for advanced HCC. Only one third of patients achieve an objective response with ICI-based therapies due to primary resistance or acquired resistance. The liver tumor microenvironment is naturally immunosuppressive, and specific mutations in cell signaling pathways allow the tumor to evade the immune response. Next, gene sequencing of the tumor tissue or circulating tumor DNA may delineate resistance mechanisms to ICI-based therapy and provide a rationale for novel combination therapies. In this review, we discuss the results of key clinical trials that have led to approval of ICI-based therapy options in advanced HCC and summarize the ongoing clinical trials. We review resistance mechanisms to ICIs and discuss how immunotherapies may be optimized based on the emerging research of tumor biomarkers and genomic alterations. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases

Author

Reid, Michelle D, Balci, Serdar, Ohike, Nobuyuki, Xue, Yue, Kim, Grace E, Tajiri, Takuma, Memis, Bahar, Coban, Ipek, Dolgun, Anil, Krasinskas, Alyssa M, Basturk, Olca, Kooby, David A, Sarmiento, Juan M, Maithel, Shishir K, El-Rayes, Bassel F, and Adsay, Volkan

Published
2016
Full Text
View/download PDF

49. Abstract LB322: Antitumor activity of 1st-in-class pan-RAS inhibitor ADT-1004 in mouse models of pancreatic ductal adenocarcinoma

Author

Maxuitenko, Yulia Y., primary, Foote, Jeremy B., additional, Keeton, Adam B., additional, Chen, Xi, additional, Berry, Kristy, additional, Fadlalla, Khalda, additional, Valiyaveettil, Jacob, additional, Huang, Chung-Hui, additional, Moore, Austin M., additional, Graff, Emily C., additional, Nagaraju, Ganji P., additional, Carstens, Julienne L., additional, El-Rayes, Bassel F., additional, Buchsbaum, Donald J., additional, and Piazza, Gary A., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results